PACS Group, Inc. PACS Group (PACS) shares jumped more than 7% on Tuesday after the company announced plans to acquire the operations of 34 skilled nursing facilities from Eduro Healthcare. The deal expands PACS's post-acute care portfolio significantly, adding 3,633 beds across 22 facilities in Texas, six in Montana, three in South Dakota, and one each in New Mexico, North Dakota, and Utah. Financial terms weren't disclosed.
"We're thrilled to welcome these 34 facilities, as well as their staff and residents, to the PACS family," said Chairman and CEO Jason Murray. President and COO Josh Jergensen added that the two companies share similar operating models and patient care philosophies. Eduro Managing Director Mike Bewsey said PACS was chosen for its commitment to preserving the company's culture and supporting employees.
The transaction is expected to close in multiple tranches, with most facilities anticipated to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions.
Technical Picture Remains Bullish
PACS continues to trade well above its 20-day, 50-day, 100-day, and 200-day simple moving averages, signaling a strong long-term uptrend. The stock has maintained a bullish "golden cross" since October 2025, with the 50-day moving average remaining above the 200-day moving average. Momentum indicators also support the rally: the MACD sits above its signal line, and a positive histogram suggests buying pressure is strengthening.
With the stock trading close to its 52-week high of $43.08, traders will watch whether it can break to new highs or pull back. Nearby support is around $34.50, where buyers have previously emerged.
Analyst Consensus & Recent Actions
The stock carries a Strong Buy rating with an average price forecast of $49.00. Recent analyst moves include:
- Truist Securities: Buy (raises forecast to $52.00) on May 18
- Oppenheimer: Outperform (raises forecast to $48.00) on May 13
- UBS: Buy (raises forecast to $44.00) on March 4
PACS Group shares were up 7.54% at $42.95 at the time of publication on Tuesday.